Operates a small consulting, advisory and financial services business, listed on the BSE Startup Platform. Revenue from operations came in at Rs 18 lakhs in FY26, up from Rs 8.25 lakhs in FY25 and nil in FY24. The company reported a net profit of Rs 8.64 lakhs in FY26 against Rs 0.90 lakhs in FY25, although operating cash flow was negative at Rs 0.55 lakhs. Total assets stood at Rs 77.81 lakhs at end-FY26 with cash balances of Rs 1.36 lakhs and no capex during the year. The board has approved a special resolution to change the company's name to 'ACME Fintech Limited' or 'ACME Global' to reflect what management describes as its fintech, broking and advisory focus. Employee costs at 11.3% of revenue and other operating expenses at 16.4% are the main cost items; materials and capex were nil in FY26. AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. Consulting, advisory and financial services. Micro-cap services and advisory entity on the BSE Startup Platform
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| EBITDA (ex other income) | — | — | — | 0 | — |
| margin % | — | — | — | 50.2 | — |
| Owners' profit | — | — | — | 0 | — |
| EPS, as reported (₹) | (6.23) | (1.70) | 0.00 | 0.02 | 0.22 |
| ROE % · ROCE % | — · (39.4) | — · (12.0) | — · (20.4) | 2.0 · 0.9 | — · 14.6 |
| Debt / equity (x) | — | — | — | 0.22 | — |
| Cash from operations | (0) | 0 | 1 | (0) | 0 |
| Capex | — | — | — | 0 | 0 |
| ₹ crore | Q2 FY23 | Q4 FY23 | Q2 FY24 | Q4 FY24 | Q2 FY25 | Q4 FY25 | Q2 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 0 | (0) | (0) | (0) | (0) | 0 | 0 | 0 |
| Net profit | 0 | — | — | — | — | 0 | — | — |
| EPS (₹) | 1.22 | (1.70) | (1.21) | 0.00 | (0.13) | 0.13 | 0.13 | 0.10 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| POLY MEDICURE LIMITED | 17,626 | 55.9 | 5.60 | 32.3 | 10.2 | 12.6 | 19.0 | 30.2 |
| FISCHER MEDICAL VENTURE L | 2,353 | 15.0 | 6.11 | 43.6 | 8.1 | 11.3 | — | 15.5 |
| TARSONS PRODUCTS LIMITED | 1,657 | 149.0 | 2.61 | 14.3 | 2.3 | 2.4 | — | 29.0 |
| LAXMI DENTAL LIMITED | 1,121 | 36.0 | 4.59 | 24.1 | 11.8 | 11.0 | — | 22.3 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 10 Sept 2026 · Book closure for 13th AGM on September 29, 2026 | board shareholder meetings | low | — | — |
| 5 Sept 2026 · Notice of 13th AGM on 29 September 2026 at 4:00 PM via video conference | board shareholder meetings | low | — | — |
| 5 Sept 2026 · Transpact Enterprises FY26 Annual Report: Revenue up 118%, PAT jumps to Rs 8.04 lakh | results | high | — | — |
| 4 Sept 2026 · Revised Board Meeting Outcome: AGM and Annual Report Approved | management changes | medium | — | — |
| 4 Sept 2026 · Board meeting outcome - Annual Report approved, 13th AGM finalized | results | high | — | — |
| 1 Sept 2026 · Board Meeting on 4 Sep 2026 to approve FY26 results and AGM | results | low | — | — |
| 14 Jul 2026 · Reg 74(5) Certificate for Q1 FY27 Filed | compliance | minimal | — | — |
| 1 Jul 2026 · CFO Ms. Komal Dwivedi resigns effective June 30, 2026 | management changes | high | — | — |
| 30 May 2026 · Transpact Enterprises Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026. | results | high | — | — |
| 23 May 2026 · Transpact Enterprises Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2026 ,inter alia, to consider and approve Audited Financial Statements .... | results | low | — | — |
| Where a broker report shows | This document shows |
|---|
| FABTECH TECHNOLOGIES LTD |
| 650 |
| 10.6 |
| 1.55 |
| 10.6 |
| 9.1 |
| 10.7 |
| — |
| 9.9 |
| Hemant Surgical Industries Lim | 613 | 23.4 | — | — | — | 16.7 | — | — |
| Prevest Denpro Limited | 489 | 16.5 | — | — | — | 21.9 | — | — |
| NURECA LIMITED | 318 | 65.2 | 1.76 | 38.3 | 1.2 | 2.7 | (7.2) | 13.0 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 355.8 | 20.0 | 17 of 17 | 0% |
| ROCE | 14.6 | 11.3 | 6 of 17 | 69% |
| Market cap | 3 | 175 | 17 of 17 | 0% |
| Why |
|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
